Cancer Cell Coating Nanoparticles for Optimal Tumor-Specific Cytokine Delivery.

Although cytokine therapy is an attractive strategy to build a more robust immune response in tumors, cytokines have faced clinical failures due to toxicity. In particular, interleukin-12 has shown great clinical promise but was limited in translation due to systemic toxicity. In this study, we demonstrate an enhanced ability to reduce toxicity without affecting efficacy of IL-12 therapy. We engineer the material properties of a NP to meet the enhanced demands for optimal cytokine delivery by using the layer-by-layer (LbL) approach. Importantly, using LbL, we demonstrate cell-level trafficking of NPs to preferentially localize to the cell's outer surface and act as a drug depot, which is required for optimal payload activity on neighboring cytokine membrane receptors. LbL-NPs showed efficacy against a tumor challenge in both colorectal and ovarian tumors at doses that were not tolerated when administered carrier-free.

[1]  P. Hammond,et al.  Tuning Nanoparticle Interactions with Ovarian Cancer through Layer by Layer Modification of Surface Chemistry. , 2020, ACS nano.

[2]  N. Borys,et al.  Phase I study of the safety and activity of formulated IL-12 plasmid administered intraperitoneally in combination with neoadjuvant chemotherapy in patients with newly diagnosed advanced-stage ovarian cancer. , 2019, Journal of Clinical Oncology.

[3]  K. Wittrup,et al.  What, Why, Where, and When: Bringing Timing to Immuno-Oncology. , 2019, Trends in immunology.

[4]  D. Felsher,et al.  Lipid nanoparticles that deliver IL-12 messenger RNA suppress tumorigenesis in MYC oncogene-driven hepatocellular carcinoma , 2018, Journal of Immunotherapy for Cancer.

[5]  F. Marincola,et al.  International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study , 2018, The Lancet.

[6]  Charles Schmidt.  The benefits of immunotherapy combinations , 2017, Nature.

[7]  P. Hammond,et al.  A Combination RNAi-Chemotherapy Layer-by-Layer Nanoparticle for Systemic Targeting of KRAS/P53 with Cisplatin to Treat Non–Small Cell Lung Cancer , 2017, Clinical Cancer Research.

[8]  J. Wolchok,et al.  Combination immunotherapy: a road map , 2017, Journal of Immunotherapy for Cancer.

[9]  I. Mellman,et al.  Elements of cancer immunity and the cancer–immune set point , 2017, Nature.

[10]  Paula T Hammond,et al.  Engineering nanolayered particles for modular drug delivery. , 2016, Journal of controlled release : official journal of the Controlled Release Society.

[11]  A. Belcher,et al.  Layer-by-layer assembled fluorescent probes in the second near-infrared window for systemic delivery and detection of ovarian cancer , 2016, Proceedings of the National Academy of Sciences.

[12]  Kasper Renggli,et al.  Highly Scalable, Closed‐Loop Synthesis of Drug‐Loaded, Layer‐by‐Layer Nanoparticles , 2016, Advanced functional materials.

[13]  S. Murphy,et al.  Chemotherapy Induces Programmed Cell Death-Ligand 1 Overexpression via the Nuclear Factor-κB to Foster an Immunosuppressive Tumor Microenvironment in Ovarian Cancer. , 2015, Cancer research.

[14]  Kevin E. Shopsowitz,et al.  Tumor-Targeted Synergistic Blockade of MAPK and PI3K from a Layer-by-Layer Nanoparticle , 2015, Clinical Cancer Research.

[15]  N. Matsumura,et al.  IFN-γ from lymphocytes induces PD-L1 expression and promotes progression of ovarian cancer , 2015, British Journal of Cancer.

[16]  D. Zaharoff,et al.  Intravesical chitosan/interleukin-12 immunotherapy induces tumor-specific systemic immunity against murine bladder cancer , 2015, Cancer Immunology, Immunotherapy.

[17]  D. Zaharoff,et al.  Neoadjuvant immunotherapy with chitosan and interleukin-12 to control breast cancer metastasis , 2014, Oncoimmunology.

[18]  Paula T. Hammond,et al.  Bimodal Tumor-Targeting from Microenvironment Responsive Hyaluronan Layer-by-Layer (LbL) Nanoparticles , 2014, ACS nano.

[19]  Erik C. Dreaden,et al.  A Nanoparticle-Based Combination Chemotherapy Delivery System for Enhanced Tumor Killing by Dynamic Rewiring of Signaling Pathways , 2014, Science Signaling.

[20]  Dan Peer,et al.  Modulation of drug resistance in ovarian adenocarcinoma using chemotherapy entrapped in hyaluronan-grafted nanoparticle clusters. , 2014, ACS nano.

[21]  J. Galon,et al.  The immune landscape of human tumors , 2014, Oncoimmunology.

[22]  Arun K Iyer,et al.  In vivo biodistribution of siRNA and cisplatin administered using CD44-targeted hyaluronic acid nanoparticles. , 2013, Journal of controlled release : official journal of the Controlled Release Society.

[23]  Paula T Hammond,et al.  Layer-by-layer nanoparticles for systemic codelivery of an anticancer drug and siRNA for potential triple-negative breast cancer treatment. , 2013, ACS nano.

[24]  I. Mellman,et al.  Oncology meets immunology: the cancer-immunity cycle. , 2013, Immunity.

[25]  P. Hammond,et al.  The architecture and biological performance of drug-loaded LbL nanoparticles. , 2013, Biomaterials.

[26]  D. Zaharoff,et al.  Role of chitosan co-formulation in enhancing interleukin-12 delivery and antitumor activity. , 2013, Biomaterials.

[27]  F. Marincola,et al.  Cancer classification using the Immunoscore: a worldwide task force , 2012, Journal of Translational Medicine.

[28]  Shouli Wang,et al.  Prevention of colorectal cancer liver metastasis by exploiting liver immunity via chitosan-TPP/nanoparticles formulated with IL-12. , 2012, Biomaterials.

[29]  Paula T. Hammond,et al.  Engineering materials layer‐by‐layer: Challenges and opportunities in multilayer assembly , 2011 .

[30]  Kwangmeyung Kim,et al.  Smart nanocarrier based on PEGylated hyaluronic acid for cancer therapy. , 2011, ACS nano.

[31]  S. Venkatraman,et al.  Layer-by-layer microcapsules templated on erythrocyte ghost carriers. , 2011, International journal of pharmaceutics.

[32]  Takeshi Shimizu,et al.  Nanogel DDS enables sustained release of IL-12 for tumor immunotherapy. , 2008, Biochemical and biophysical research communications.

[33]  A. Chang,et al.  Synergistic effect of intratumoral IL-12 and TNF-alpha microspheres: systemic anti-tumor immunity is mediated by both CD8+ CTL and NK cells. , 2007, Surgery.

[34]  J. Weiss,et al.  Immunotherapy of cancer by IL-12-based cytokine combinations , 2007, Expert opinion on biological therapy.

[35]  Frank Caruso,et al.  Layer-by-layer engineered capsules and their applications , 2006 .

[36]  P. Hammond.  Form and Function in Multilayer Assembly: New Applications at the Nanoscale , 2004 .

[37]  M. Looman,et al.  Pharmacokinetics and immunological aspects of a phase Ib study with intratumoral administration of recombinant human interleukin-12 in patients with head and neck squamous cell carcinoma: a decrease of T-bet in peripheral blood mononuclear cells. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[38]  M. Sabel,et al.  Cancer immunotherapy with interleukin 12 and granulocyte-macrophage colony-stimulating factor-encapsulated microspheres: coinduction of innate and adaptive antitumor immunity and cure of disseminated disease. , 2002, Cancer research.

[39]  Mathias Winterhalter,et al.  Protein encapsulation in liposomes: efficiency depends on interactions between protein and phospholipid bilayer. , 2002, BMC biotechnology.

[40]  G. Trinchieri,et al.  Interleukin-12 in anti-tumor immunity and immunotherapy. , 2002, Cytokine & growth factor reviews.

[41]  M. Sabel,et al.  Neoadjuvant therapy with interleukin-12-loaded polylactic acid microspheres reduces local recurrence and distant metastases. , 2001, Surgery.

[42]  M. Sabel,et al.  In situ tumor vaccination with interleukin-12-encapsulated biodegradable microspheres: induction of tumor regression and potent antitumor immunity. , 2000, Cancer research.

[43]  M. Schuler,et al.  Phase I study of subcutaneously administered recombinant human interleukin 12 in patients with advanced renal cell cancer. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[44]  M. Gordon,et al.  IL-12 is a heparin-binding cytokine. , 1999, Journal of immunology.

[45]  G. Trinchieri,et al.  Interleukin-12: basic principles and clinical applications. , 1999, Current topics in microbiology and immunology.

[46]  Gero Decher,et al.  Fuzzy Nanoassemblies: Toward Layered Polymeric Multicomposites , 1997 .

[47]  M. Atkins,et al.  Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[48]  Gero Decher,et al.  Toward Layered Polymeric Multicomposites , 1997 .

[49]  M. Colombo,et al.  Amount of interleukin 12 available at the tumor site is critical for tumor regression. , 1996, Cancer research.

[50]  Robertson,et al.  Interleukin 12: Basic Biology and Potential Applications in Cancer Treatment. , 1996, The oncologist.

[51]  G. Trinchieri.  Interleukin-12: a proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptive immunity. , 1995, Annual review of immunology.

[52]  L. Luistro,et al.  Antitumor and antimetastatic activity of interleukin 12 against murine tumors , 1993, The Journal of experimental medicine.

[53]  J C Stewart,et al.  Colorimetric determination of phospholipids with ammonium ferrothiocyanate. , 1980, Analytical biochemistry.